From the results of drug sensitivity, we found that patients with low risk are more sensitive to PI3K inhibitor, JAK inhibitor, IGF-1R inhibitor, MAPK inhibitor, JAK inhibitor and PI3KCA inhibitor, which indicated that low risk COAD patients might benefit from these drugs. The gene discussed is IGF1R; the disease is colon adenocarcinoma.